Aurinia Pharmaceuticals (AUPH) has released an update.
Aurinia Pharmaceuticals reported the outcomes of its 2024 annual general meeting, where shareholders re-elected five of nine incumbent directors, despite four receiving less than majority support and thus tendering conditional resignations. The company’s reappointment of PricewaterhouseCoopers as its auditor was approved, but proposals for executive compensation and an amendment to the equity incentive plan were not. The company remains committed to enhancing shareholder value and continuing the delivery of its FDA-approved lupus nephritis treatment, LUPKYNIS.
For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.
